An Open-label, Dose-ascending Study of IGT001 for Retinitis Pigmentosa

NCT06936787 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

21

Enrollment

OTHER

Sponsor class

Conditions

Retinitis Pigmentosa

Interventions

DRUG: IGT001

Sponsor

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine